Oncologist: BRAF mutation is associated with poor prognosis in mismatch repair deletion (MMR-D)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC)

Mismatch repair gene deletion (MMR-D)/high microsatellite instability (MSI-H) metastaticColorectal cancer (mCRC) is a distinct subtype that is attracting increasing attention with an increase in young colorectal cancers
.
Recently, a foreign retrospective study was published in the journal Oncologist, mainly evaluating the clinical disease of mismatch repair gene deletion (MMR-D)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC).

Physiological features and prognostic factors

Mismatch repair gene deletion (MMR-D)/high microsatellite instability (MSI-H) metastaticColorectal cancer (mCRC) is a distinct subtype that is attracting increasing attention with an increase in young colorectal cancers

The retrospective study included 1101 patients, most of whom (79.

9%) were older than 50 years

The retrospective study included 1101 patients, most of whom (79.

BRAF mutation in patients >50 years old (52% vs 14.

BRAF mutant patients had worse OS than BRAF wild-type patients, with median survival of 18.

9 months and 33.

BRAF mutant patients had worse OS than BRAF wild-type patients, with median survival of 18.

Compared with wild-type RAS patients, patients with RAS mutations had prolonged OS, with a median OS of 35.

7 months and 22.

Compared with wild-type RAS patients, patients with RAS mutations had prolonged OS, with a median OS of 35.

There was no significant difference in OS for colon and rectum, 23.

1 months and 24.

There was no significant difference in OS for colon and rectum, 23.

In multivariate analysis, increasing age, ECOG 2-4 (HR 1.
87, 95% CI: 1.
38-2.
54, P<.
0001 ci: p="0.
0121) was still associated with worse survival outcomes, while immunotherapy (HR " ci>

In multivariate analysis, increasing age, ECOG 2-4 (HR 1.
87, 95% CI: 1.
38-2.
54, P<.
0001 ci: p="0.
0121) was still associated with worse survival outcomes, while immunotherapy (HR " ci> In multivariate analysis, increasing age, ECOG 2-4 (HR 1.
87, 95% CI: 1.
38-2.
54, P<.
0001 ci: p="0.
0121) was still associated with poorer survival outcomes, while immunization Treatment (HR" ci> <.
0001 ci: p="0.
0121) was still associated with worse survival outcomes, while immunotherapy (HR" ci>

In conclusion, the study showed that in patients with mismatch repair gene deletion (MMR-D) metastatic colorectal cancer (mCRC), BRAF mutation and age >50 years were associated with poor prognosis, and immunotherapy could improve the prognosis of patients
.

In conclusion, the study showed that in patients with mismatch repair gene deletion (MMR-D) metastatic colorectal cancer (mCRC), BRAF mutation and age >50 years were associated with poor prognosis, and immunotherapy could improve the prognosis of patients
.
Studies have shown that BRAF mutation and age >50 years are associated with poor prognosis in patients with mismatch repair gene deletion (MMR-D) metastatic colorectal cancer (mCRC), and immunotherapy can improve the prognosis of patients
.
Studies have shown that BRAF mutation and age >50 years are associated with poor prognosis in patients with mismatch repair gene deletion (MMR-D) metastatic colorectal cancer (mCRC), and immunotherapy can improve the prognosis of patients
.

Original source:

Original source:

Elaine Tan , Junmin Whiting, Hao Xie, et al.
BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/ Microsatellite High Colorectal Cancer.
The Oncologist, 2022, 27, 191–197 https://doi.
org/10.
1093/oncolo/oyab055.
 

Elaine Tan , Junmin Whiting, Hao Xie, et al.
BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/ Microsatellite High Colorectal Cancer.
The Oncologist, 2022, 27, 191–197 https://doi.
org/10.
1093/oncolo/oyab055.
  Leave a message here